ABVC: ABVC BioPharma Inc. P/S Multiple
P/S volatility on GURU.Markets reflects the market risks facing ABVC BioPharma in the presence of major pharma behemoths, with the current parameter equal to 43.70. ABVC BioPharma develops plant-based treatments for ADHD and depression, scaling sales through global licensing. The asset's value growth is based on FDA approvals, patent expansion, and payments from Asian partners.
ABVC BioPharma Inc (ABVC) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio ABVC BioPharma|ABVC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ABVC BioPharma, Inc|ABVC - Company Aggregate Debts|Debt to Book Capitalization Ratio ABVC BioPharma Inc|ABVC - Company Long-Term Debts|Short-Term Debt Volume ABVC BioPharma|Immediate Liquidity abvcpharma.com
- financial results and valuation multiples details:
ABVC - Company Net Income|Forward Earnings ABVC BioPharma|ABVC - P/E Multiple|Future Price to Earnings Multiple ABVC BioPharma Inc.|ABVC - PEG Multiple|EV/EBITDA Multiple ABVC BioPharma Inc|ABVC - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year ABVC BioPharma|ABVC - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months abvcpharma.com|ABVC - Earnings growth in current year|Earnings growth forecast for next year ABVC BioPharma
- sales revenue and business income indicators:
General company analysis:abvcpharma.com ABVC
Professional managers utilize fundamental filters to separate overvalued assets from those with growth potential. The P/S ratio compares market capitalization to annual revenue, determining the cost of one ruble of sales within the share price. For ABVC BioPharma, which depends on investments and research outcomes, this metric reflects market expectations for future products. Analyzing the P/S ratio chart helps balance risk and potential return.
Competing companies
HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|P/S Multiple Verona Pharma PLC VRNA|Jyong Biotech Corp - P/S Multiple|LGND: Price-to-Revenue Ratio|AMRX (Amneal Pharmaceuticals) - Market Cap to Revenue|PRGO (perrigo.com) - Price-to-Revenue Ratio|ALVO (Alvotech SA) - P/S Multiple|Market Cap to Revenue Liquidia Corp (LQDA)|Market Cap to Revenue GLPG (Galapagos Genomics)|ANIP (ANI Pharmaceuticals Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple MNKD (MannKind Corporation)|amphastar.com - Price-to-Revenue Ratio|Pacira BioSciences, Inc. - P/S Multiple|Price-to-Revenue Coefficient ARS Pharmaceuticals Inc SPRY|Theravance (TBPH) - Price-to-Revenue Ratio|Price to Sales Aquestive Corp (AQST)|Price-to-Revenue Ratio scPharmaceuticals, Inc.|Tectonic - Price-to-Sales Ratio|P/S Multiple TNXP|SXTC (sxtchina.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|P/S Multiple BioHarvest Sciences Inc BHST|EXOZ - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ORMP (Oramed Pharmaceuticals)|enterabio.com (ENTX) - Price-to-Revenue Ratio|Market Cap to Revenue MindWalk Holdings, Inc.|CPIX (Cumberland Pharma) - P/S Multiple|P/S Multiple Quantum BioPharma Corp|P/S Multiple FGEN|P/S Multiple telomirpharma.com (TELO)|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|Synergy CHC Corp. - Price-to-Revenue Ratio|RLYB: Market Cap to Revenue|LEXX: Price-to-Revenue Ratio|PULM: P/S Multiple|Market Cap to Revenue Pheton Holdings|Price-to-Revenue Ratio Aptorum Group Ltd|Lyra Therapeutics Inc. - Price-to-Sales Ratio|P/S Multiple IBO|TNFA (tnfpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple YCBD (cbdMD)|P/S Multiple painreform.com PRFX|CYTO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio LIPO (Lipella Pharmaceuticals Inc)|Optinose (OPTN) - Price-to-Revenue Ratio|Market Cap to Revenue Pieris Pharma|PROC (Procaps Group S.A.) - P/S Multiple|P/S Multiple petrospharma.com|Market Cap to Revenue QLI (Qilian International Holding)|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TFF Pharma TFFP
